Antipodean Advisors’s AstraZeneca AZN Stock Holding History

Antipodean Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-266,000	Closed	-$19.8M	–	27
2014 Q2	$19.8M	Buy	+266,000	New	+$19.2M	1.48%	17

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Antipodean Advisors's AZN Position: Q3 2014 in Review

Antipodean Advisors sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 266,000 shares — an estimated $19.8M sold.

Antipodean Advisors first reported a position in AZN in Q2 2014 and held it in 1 quarter. The position peaked at $19.8M in Q2 2014. 402 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

Antipodean Advisors reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
Antipodean Advisors sold 266,000 AstraZeneca shares in Q3 2014, an estimated $19.8M.
Antipodean Advisors first reported a position in AstraZeneca in Q2 2014 and held it in 1 quarter.
Antipodean Advisors's AstraZeneca position peaked at $19.8M in Q2 2014.
402 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on Antipodean Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.